
Arpad Marki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5294584/publications.pdf Version: 2024-02-01



Δρολη Μλρκι

#	Article	IF	CITATIONS
1	Allosteric activation of metabotropic glutamate receptor 5. Journal of Biomolecular Structure and Dynamics, 2020, 38, 2624-2632.	3.5	7
2	Preparation and investigation of core-shell nanoparticles containing human interferon-α. International Journal of Pharmaceutics, 2020, 573, 118825.	5.2	16
3	Preparation and characterization of lamotrigine containing nanocapsules for nasal administration. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 153, 177-186.	4.3	12
4	Investigation of the Absorption of Nanosized lamotrigine Containing Nasal Powder via the Nasal Cavity. Molecules, 2020, 25, 1065.	3.8	11
5	Nasal delivery of nanosuspension-based mucoadhesive formulation with improved bioavailability of loratadine: Preparation, characterization, and in vivo evaluation. International Journal of Pharmaceutics, 2020, 579, 119166.	5.2	37
6	Development of Meloxicam-Human Serum Albumin Nanoparticles for Nose-to-Brain Delivery via Application of a Quality by Design Approach. Pharmaceutics, 2020, 12, 97.	4.5	31
7	Transformation of Meloxicam Containing Nanosuspension into Surfactant-Free Solid Compositions to Increase the Product Stability and Drug Bioavailability for Rapid Analgesia. Drug Design, Development and Therapy, 2019, Volume 13, 4007-4020.	4.3	10
8	Detection of stress and the effects of central nervous system depressants by gastrointestinal smooth muscle electromyography in wakeful rats. Life Sciences, 2018, 205, 1-8.	4.3	4
9	Investigation of Absorption Routes of Meloxicam and Its Salt Form from Intranasal Delivery Systems. Molecules, 2018, 23, 784.	3.8	18
10	Effect of solubility enhancement on nasal absorption of meloxicam. European Journal of Pharmaceutical Sciences, 2016, 95, 96-102.	4.0	19
11	Study of sodium hyaluronate-based intranasal formulations containing micro- or nanosized meloxicam particles. International Journal of Pharmaceutics, 2015, 491, 198-207.	5.2	33
12	Investigation of the Pharmacokinetics of the ABCG2 Transporter Inhibitor Ko134 in Mice by a Newly Developed and Validated HPLC Method. Current Pharmaceutical Analysis, 2014, 10, 30-37.	0.6	0
13	In vitro and in vivo characterization of meloxicam nanoparticles designed for nasal administration. European Journal of Pharmaceutical Sciences, 2013, 50, 86-92.	4.0	47
14	Metabolic Effects of Mulberry Leaves: Exploring Potential Benefits in Type 2 Diabetes and Hyperuricemia. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-10.	1.2	30
15	In silico and in vitro pharmacological investigations of a natural alkaloid. Medicinal Chemistry Research, 2012, 21, 4100-4107.	2.4	0
16	Antiproliferative effect of normal and 13-epi-d-homoestrone and their 3-methyl ethers on human reproductive cancer cell lines. Journal of Steroid Biochemistry and Molecular Biology, 2012, 132, 168-175.	2.5	25
17	β2-Adrenergic activity of 6-methoxykaempferol-3-O-glucoside on rat uterus: In vitro and in silico studies. European Journal of Pharmacology, 2011, 667, 348-354.	3.5	7
18	An Intraperitoneally Administered Pentapeptide Protects Against Aβ1–42 Induced Neuronal Excitation In Vivo. Journal of Alzheimer's Disease, 2009, 16, 189-196.	2.6	19

ARPAD MARKI

#	Article	IF	CITATIONS
19	Inflammatory processes enhance cAMP-mediated uterus relaxation in the pregnant rat: the role of TNF-α. Naunyn-Schmiedeberg's Archives of Pharmacology, 2009, 379, 501-510.	3.0	5
20	Phytoecdysteroids and Anabolic-Androgenic Steroids - Structure and Effects on Humans. Current Medicinal Chemistry, 2008, 15, 75-91.	2.4	156
21	3D QSAR models for α2a-adrenoceptor agonistsâ~†. Neurochemistry International, 2007, 51, 268-276.	3.8	5
22	Modeling the human oxytocin receptor for drug discovery efforts. Expert Opinion on Drug Discovery, 2007, 2, 1579-1590.	5.0	1
23	Receptor-based QSAR studies of non-peptide human oxytocin receptor antagonists. Journal of Molecular Graphics and Modelling, 2007, 25, 711-720.	2.4	10
24	The effects of αâ€methyldopa on myometrial noradrenaline release and myometrial contractility in rat. Acta Obstetricia Et Gynecologica Scandinavica, 2007, 86, 986-994.	2.8	2
25	Neighboring group participation. Steroids, 2006, 71, 141-153.	1.8	6
26	Comparative study of eight oxytocin antagonists by simulated annealing. Journal of Molecular Modeling, 2006, 12, 823-828.	1.8	4
27	Possible dynamic anchor points in a benzoxazinone derivative–human oxytocin receptor system — a molecular docking and dynamics calculation. Journal of Molecular Modeling, 2006, 13, 1-10.	1.8	6
28	The 3D Structure of the Binding Pocket of the Human Oxytocin Receptor for Benzoxazine Antagonists, Determined by Molecular Docking, Scoring Functions and 3D-QSAR Methods. Journal of Computer-Aided Molecular Design, 2005, 19, 341-356.	2.9	13
29	Pregnancy-induced decrease in the relaxant effect of terbutaline in the late-pregnant rat myometrium: role of C-protein activation and progesterone. Reproduction, 2005, 130, 113-122.	2.6	27
30	Investigation of estrogen receptor \hat{I}_{\pm} and \hat{I}^2 mRNA expression in the pregnant rat uterus. Molecular Reproduction and Development, 2004, 68, 463-468.	2.0	12
31	The role of androgen receptors in the dynamic process of prostate cancer: their analytical determination in biopsy material. In Vivo, 2004, 18, 809-12.	1.3	1
32	α-Adrenergic blockade: a possible mechanism of tocolytic action of certain benzodiazepines in a postpartum rat model in vivo. Life Sciences, 2003, 72, 1093-1102.	4.3	5
33	Synthesis and receptor-binding examinations of the normal and 13-epi-D-homoestrones and their 3-methyl ethers. Steroids, 2003, 68, 277-288.	1.8	30
34	Kappa-receptor selective binding of opioid ligands with a heterocyclic bicyclo[3.3.1]nonan-9-one structure. Acta Biologica Hungarica, 2003, 54, 147-155.	0.7	4
35	Synthesis and receptor-binding examination of 16-hydroxymethyl-3,17-estradiol stereoisomers. Steroids, 2002, 67, 371-377.	1.8	8
36	Erratum to â€~synthesis and receptor-binding examination of 16-hydroxymethyl-3,17-estradiol stereoisomers' [Steroids 67 (2002) 371–377]. Steroids, 2002, 67, 669.	1.8	0

ARPAD MARKI

#	Article	IF	CITATIONS
37	Synthesis and receptor-binding examination of 16-hydroxymethyl-3,17-estradiol stereoisomers. Steroids, 2002, 67, 671-678.	1.8	15
38	Noncompetitive nature of oxytocin antagonists with general structure Mpa1Xxx2Sar7Arg8. Peptides, 2002, 23, 1419-1425.	2.4	11
39	Characterization of late-pregnant rat uterine contraction via the contractility ratio in vitro Significance of α1-adrenoceptors. Life Sciences, 2001, 68, 1119-1129.	4.3	16
40	Use of Antisense Oligonucleotides to Verify the Role of the α _{1A} -Adrenergic Receptor in the Contractility of the Rat Uterus Post Partum. Molecular Pharmacology, 2001, 59, 1235-1242.	2.3	9
41	μ-Opioid receptor specific antagonist cyprodime: characterization by in vitro radioligand and [35S]CTPγS binding assays. European Journal of Pharmacology, 1999, 383, 209-214.	3.5	38
42	Tritiated kappa receptor antagonist norbinaltorphimine: Synthesis and in vitro binding in three different tissues. Life Sciences, 1999, 66, 43-49.	4.3	9
43	Evidence of non-synaptic regulation of postpartum uterine contractility in the rat. Life Sciences, 1998, 62, 1119-1124.	4.3	14
44	Correlation between alpha1/beta-adrenoceptor ratio and spontaneous uterine motor activity in the post-partum rat. Molecular Human Reproduction, 1998, 4, 921-924.	2.8	8
45	New nepenthone and thevinone derivatives. Bioorganic and Medicinal Chemistry, 1997, 5, 369-382.	3.0	19
46	Structurally novel group of ligands selective for kappa opioid receptors. Regulatory Peptides, 1994, 54, 27-28.	1.9	15